File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Candida krusei infections and fluconazole therapy

TitleCandida krusei infections and fluconazole therapy
Authors
KeywordsAIDS- related opportunistic
Candida krusei
Candidiasis
Drug resistance, microbial
Fluconazole
Issue Date1997
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 1997, v. 3 n. 3, p. 312-314 How to Cite?
AbstractCandida species are by far the most common agents of mucosal fungal infection in man. While Candida albicans is the most notorious pathogen in this group, non-albicans species such as Candida krusei are gradually emerging as pathogens of concern, especially in compromised hosts. It is thought that the wide use of the newer triazole drug, fluconazole, in HIV- infected individuals is contributing to this phenomenon. Studies in both humans and animals have now demonstrated prophylactic and therapeutic failure of fluconazole against C. krusei due to increasing resistance of the organism to this azole. Thus, the indiscriminate use of fluconazole, a drug with relatively minimal toxicity and excellent pharmacokinetics, may lead to the development of widespread resistance to this azole among Candida species.
Persistent Identifierhttp://hdl.handle.net/10722/44549
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorSamaranayake, LPen_HK
dc.date.accessioned2007-10-30T06:03:58Z-
dc.date.available2007-10-30T06:03:58Z-
dc.date.issued1997en_HK
dc.identifier.citationHong Kong Medical Journal, 1997, v. 3 n. 3, p. 312-314en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/44549-
dc.description.abstractCandida species are by far the most common agents of mucosal fungal infection in man. While Candida albicans is the most notorious pathogen in this group, non-albicans species such as Candida krusei are gradually emerging as pathogens of concern, especially in compromised hosts. It is thought that the wide use of the newer triazole drug, fluconazole, in HIV- infected individuals is contributing to this phenomenon. Studies in both humans and animals have now demonstrated prophylactic and therapeutic failure of fluconazole against C. krusei due to increasing resistance of the organism to this azole. Thus, the indiscriminate use of fluconazole, a drug with relatively minimal toxicity and excellent pharmacokinetics, may lead to the development of widespread resistance to this azole among Candida species.en_HK
dc.format.extent168372 bytes-
dc.format.extent2166 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAIDS- related opportunisticen_HK
dc.subjectCandida kruseien_HK
dc.subjectCandidiasisen_HK
dc.subjectDrug resistance, microbialen_HK
dc.subjectFluconazoleen_HK
dc.titleCandida krusei infections and fluconazole therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=3&issue=3&spage=312&epage=4&date=1997&atitle=Candida+krusei+infections+and+fluconazole+therapyen_HK
dc.identifier.emailSamaranayake, LP:lakshman@hku.hken_HK
dc.identifier.authoritySamaranayake, LP=rp00023en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11847378en_HK
dc.identifier.scopuseid_2-s2.0-0031473844en_HK
dc.identifier.hkuros29678-
dc.identifier.volume3en_HK
dc.identifier.issue3en_HK
dc.identifier.spage312en_HK
dc.identifier.epage314en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridSamaranayake, LP=7102761002en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats